etentamig + pomalidomide + dexamethasone

Etentamig + pomalidomide + dexamethasone is an **investigational combination therapy** for relapsed/refractory multiple myeloma. - **Etentamig** (ABBV-383) is a bispecific T-cell engager (TCE) monoclonal antibody that targets B-cell maturation antigen (**BCMA**) on myeloma cells and CD3 on T cells, directing immune attack against myeloma cells. - **Pomalidomide** is an immunomodulatory agent (IMiD) that has direct anti-myeloma activity, enhances immune function, and modulates cytokine production. - **Dexamethasone** is a synthetic glucocorticoid used here for its anti-inflammatory and anti-myeloma effects. The combination aims for enhanced anti-myeloma efficacy over standard regimens, and is being evaluated in clinical trials for adults with multiple myeloma that is relapsed or refractory to prior lines of therapy[1][3][5].

Brand names

Pomalyst + dexamethasone (for the components, where applicable)

Other names

etentamig + Pd